DOI QR코드

DOI QR Code

Diagnostic and Clinical Significance of KIT(CD117) Expression in Thymic Epithelial Tumors in China

  • Song, Nan (Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Chen, Gang (Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Zhang, Peng (Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Liu, Ming (Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • He, Wen-Xin (Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Jiang, Ge-Ning (Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine)
  • Published : 2012.06.30

Abstract

Aims: To study KIT (CD117) expression in thymic epithelial tumors in China, and investigate diagnostic and clinical significance. Material and Methods: Thymic epithelial tumors (TETs) from 102 patients (3 type A, 29 type AB, 5 type B1, 22 type B2, 29 typeB3 and 16 thymic carcinomas) were examined. Immunohistochemical staining with an antic-kit monoclonal antibody was performed on a tissue microarray. Relationships between KIT positive expression and the TET clinical characteristics (WHO histologic classification and Masaoka stage system) were analysed. Results: The KIT positive expression rate was significantly higher in thymic carcinoma (60%, 9/16) than in thymoma (8%, 7/86), a strong correlation being found with the WHO classification, but not the Masaoka tumor stage. The overall survival for patients with KIT positive lesions was significantly worse. Conclusions: KIT is a good molecule marker to differentially diagnose thymic carcinoma from thymoma, while also serving as a predictor of prognosis for TETs. Further research into KIT mutations in Chinese TETs should be conducted to assess the efficacy of targeted therapy.

References

  1. Aisner SC, Dahlberg S, Hameed MR, et al (2010). Epidermal growth factor receptor, C-kit,and Her2/neu immunostaining in advanced or recurrentthymic epithelial neoplasms staged according to the 2004 World Health Organization in patientstreated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J Thorac Oncol, 5, 885-92. https://doi.org/10.1097/JTO.0b013e3181d86a30
  2. Arbiser JL, Govindarajan B, Bai X, et al (2002). Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis. Am J Pathol, 161, 781-6. https://doi.org/10.1016/S0002-9440(10)64237-X
  3. Corless CL, Fletcher JA, Heinrich MC (2004). Biology of gastrointestinal stromal tumors. J Clin Oncol, 22, 3813-25. https://doi.org/10.1200/JCO.2004.05.140
  4. de Jong WK, Blaauwgeers JL, Schaapveld M, et al (2008). Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer, 44, 123-30. https://doi.org/10.1016/j.ejca.2007.11.004
  5. Edling CE, Hallberg B (2007). c-Kit-a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol, 39, 1995-8. https://doi.org/10.1016/j.biocel.2006.12.005
  6. Giaccone G, Rajan A, Ruijter R, et al (2009). Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol, 4, 1270-3. https://doi.org/10.1097/JTO.0b013e3181b6be57
  7. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA (2002). Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol, 33, 484-95. https://doi.org/10.1053/hupa.2002.124124
  8. Masaoka A, Yamakawa Y, Niwa H, et al (1994). Thymectomy and malignancy. Eur J Cardiothorac Surg, 8, 251-3. https://doi.org/10.1016/1010-7940(94)90155-4
  9. Muller-Hermelink HK, Engel P, Kuo TT, et al (2004). Tumors of the thymus: introduction. In: Travis, WD.; Brambilla, E.; Muller-Hermelink, HK., et al., editors. Pathology and Genetics. Tumors of the Lung, Pleura, Thymus and Heart. WHO Classification of Tumors. Lyon: IARC Press, p146- 247.
  10. Nakagawa K, Matsuno Y, Kunitoh H, et al (2005). Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest, 128, 140-4. https://doi.org/10.1378/chest.128.1.140
  11. Pan CC, Chen PC, Chiang H (2004). Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol, 121, 878-83. https://doi.org/10.1309/A7M2XTMJQK0KPQER
  12. Petrini I, Zucali PA, Lee HS, et al (2010). Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol, 5, 1447-53. https://doi.org/10.1097/JTO.0b013e3181e96e30
  13. Strobel P, Bargou R, Wolff A, et al (2010). Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer, 103, 196-200. https://doi.org/10.1038/sj.bjc.6605740
  14. Strobel P, Hartmann M, Jakob A, et al (2004). Thymic carcinoma with overexpression of mutated KITand the response to imatinib. N Engl J Med, 350, 2625-6. https://doi.org/10.1056/NEJM200406173502523
  15. Tsuchida M, Umezu H, Hashimoto T, et al (2008). Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer, 62, 321-5. https://doi.org/10.1016/j.lungcan.2008.03.035
  16. Vandenbark GR, de Castro CM, Taylor H, et al (1992). Cloning and structural analysis of the human c-kit gene. Oncogene, 7, 1259-66.

Cited by

  1. CD117 Expression in Fibroblasts-Like Stromal Cells Indicates Unfavorable Clinical Outcomes in Ovarian Carcinoma Patients vol.9, pp.11, 2014, https://doi.org/10.1371/journal.pone.0112209
  2. Expression of PPARγ in Thymic Carcinoma and Its Prognostic Impact vol.75, pp.6, 2016, https://doi.org/10.4264/numa.75.6_293